With evidence that the number of measles cases and outbreaks this year is already well on track to exceed last year’s numbers, today’s Senate Committee on Health, Education, Labor and Pensions hearing is drawing urgent attention to a central tenet of public health: vaccines save lives.
Aid workers put their lives on the line to treat patients with Ebola. Can robots help make their jobs a little easier and allow more people to survive the disease? Bill Smart, professor of robotics at Oregon State University, is exploring how robots may be most useful during disease outbreaks.
Vaccinations are the world’s frontline defence against infectious diseases yet despite decades of interventions, unsafe injection practices continue to expose billions of people to serious infection and disease. Now, new technology from the University of South Australia is revolutionising safe vaccination practices through antibacterial, silver-loaded dissolvable microneedle patches, which not only sterilise the injection site to inhibit the growth of bacteria, but also physically dissolve after administration.
A multi-institutional, international team of researchers has developed a method that identifies individuals recently infected with Vibrio cholerae O1. The results of the study are available online in the February 20 issue of the journal Science Translational Medicine.
Mississippi State-developed vaccination technologies are being commercialized to help the catfish industry save millions for the state that leads the nation in production.
Houston Methodist scientists discovered a previously unknown trigger that turns run-of-the-mill strep infections into the flesh-eating disease childbed fever, which strikes postpartum moms and newborns, often leaving victims without limbs. Using an unprecedented approach, they looked at the interplay between the genome, transcriptome and virulence. This generated a massive data set, lending itself to artificial intelligence analysis. Through AI they unexpectedly discovered a new mechanism controlling virulence. The study appears Feb. 18 in Nature Genetics.
Collectively, assessing a snapshot of a person’s unique state of immune health is called immune profiling, which can entail identifying immune-cell-associated genes and proteins, as well as the cell types themselves.
Offering compensation can be an important tactic to attract potential participants for enrollment in research studies, but it might come at a cost. A new study conducted by researchers in the Perelman School of Medicine at the University of Pennsylvania found that up to 23 percent of respondents lied about their eligibility to participate in a survey when offered payment, even small amounts.
Using sophisticated gene sequencing and computing techniques, researchers at Vanderbilt University Medical Center (VUMC) and the San Diego Supercomputer Center have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.
Vaccines have saved millions of lives, but nobody likes getting a shot. That’s why scientists are trying to develop oral vaccines for infectious diseases. But to be effective, the vaccine must survive digestion and reach immune cells within the intestinal wall. Now, researchers reporting in the ACS journal Nano Letters have developed oral vaccines powered by micromotors that target the mucus layer of the intestine.
An international team of collaborators found that the CD4 surface protein, which is used by HIV and SIV as the receptor to enter immune cells, is highly variable among wild chimpanzees.
A vaccine against the biggest bacterial killer on the planet is a step closer to being available with funding secured for preclinical trials.
The study is the first in the world to demonstrate that chickenpox vaccine, when given to people who are already immune to it, does not trigger an unwanted “HIV-welcoming” immune state in the genital mucosa (lining) or in the bloodstream.
John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center announced today that it is leading enrollment worldwide for WIZARD 201G, a global Phase 2 study in glioblastoma (GBM). The trial, sponsored by Boston Biomedical, is evaluating DSP-7888, an investigational cancer vaccine, in combination with bevacizumab for recurrent disease.
Vanderbilt vaccine researchers are enrolling adult volunteers in a National Institutes of Health (NIH)-sponsored Phase II clinical trial that will study a next generation pertussis vaccine that may protect people from whooping cough.
A Phase 1 clinical trial of investigational vaccines intended to protect against Zaire ebolavirus (Ebola) has begun in the United States at Cincinnati Children’s Hospital Medical Center. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).
Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.
Immune cells called CD4+ T cells could be important mediators of protection against the Zika virus, according to a study published January 24 in the open-access journal PLOS Pathogens by Sujan Shresta of the La Jolla Institute for Allergy and Immunology, and colleagues. The findings support vaccine strategies that induce a protective CD4+ T cell response to the Zika virus.
Wistar scientists and collaborators demonstrated the utility of an optimized synthetic DNA vaccine platform for rapidly inducing immunity against unique combinations of tumor neoantigens.
Los Alamos National Laboratory Fellow Bette Korber will discuss her work designing a vaccine against HIV (the virus that causes AIDS) in three Frontiers in Science public lectures beginning Jan. 31 in Los Alamos.
Researchers from the National Institutes of Health have discovered that antibodies that may form the basis of a universal flu vaccine inhibit a second viral protein in addition to the one that they bind. The study, to be published January 25 in the Journal of Experimental Medicine, reveals that antibodies that recognize the viral surface protein hemagglutinin can also inhibit the viral neuraminidase, and that this enhances antibody neutralization of the virus and the activation of innate immune cells with anti-viral activity.
A new study at the Tulane National Primate Research Center showed for the first time that an experimental drug can save nonhuman primates exposed to deadly ricin toxin, a potential bioterrorism agent.
Thanks to a five-year, $3.46 million grant from the National Institute of Allergy and Infectious Diseases, Texas Tech University researchers Harvinder Gill and Steve Presley have teamed up to develop a universal flu vaccine.
Arnold Monto, professor of epidemiology at the University of Michigan School of Public Health, has been studying the spread of the flu virus and the effectiveness of vaccines and antiviral medications for more than five decades.
Getting the flu vaccine is not only your best shot at beating the virus – it could help in other ways you may never have realized.
By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving outcomes for kidney cancer patients who are at high risk of recurrence following surgery.
Gaps in the logic of how we restock flu vaccines may be costing hundreds of lives, or more. A new model to tweak the gaps could save hundreds to hundreds of thousands of people and millions to multiple millions in medical costs.
Ernst-led team will evaluate adjuvants for both antigen- and dose-sparing capabilities, which may result in decreased cost of vaccines and improved compliance in the battle against infectious diseases.
A computer-generated model developed by Johns Hopkins Medicine researchers adds to evidence that providing universal vaccination against meningitis B infection to students entering college may be too costly to justify the absolute number of cases it would prevent. The study also suggests that if vaccine developers could significantly lower the price, universal vaccination might be worth requiring on college campuses.
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people with pancreatic cancers whose response to standard immunotherapy is poor.
The HPV Vaccine is Cancer Prevention Champion Award program is a joint effort to increase the number of American young adults completing the full human papillomavirus (HPV) vaccine series.
Researchers have developed genetically modified pigs that are protected from classical swine fever virus (CSFV), according to a study published December 13 in the open-access journal PLOS Pathogens by Hongsheng Ouyang of Jilin University, and colleagues. As noted by the authors, these pigs offer potential benefits over commercial vaccination and could reduce economic losses related to classical swine fever.
People newly diagnosed with cancer, particularly blood cancers, and those treated with chemotherapy have a greater risk of developing shingles, according to a new study in the Journal of Infectious Diseases. The findings may help guide efforts to prevent the often painful skin condition in cancer patients through the use of new vaccines. The large prospective study expands on previous research by examining the risk of shingles before and after a new cancer diagnosis and across a range of cancer types among approximately 240,000 adults in Australia from 2006 to 2015.
Black adolescents living in the United States tend to receive the influenza vaccine at significantly lower rates than their white and Hispanic counterparts, according to Florida State University researchers. A new study, led by former FSU graduate student Noah Webb, along with current graduate student Benjamin Dowd-Arrow and Associate Professors of Sociology Miles Taylor and Amy Burdette, was recently published in Public Health Reports.
A team led by Duke Human Vaccine Institute researchers, publishing online Dec. 11 in the journal Immunity, reported that they have filled in a portion of the roadmap toward effective neutralization of HIV, identifying the steps that a critical HIV antibody takes to develop and maintain its ability to neutralize the virus.
Compared with last year more adults getting and intending to get a flu vaccination in 2018-19 flu season
Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cholesterol levels in the bloodstream.
The WHO considers Rift Valley fever a potential public health emergency. This study shows just how damaging the virus is during pregnancy and sets the stage for vaccine development.
In this five-day fellowship program sponsored by the Mayo Foundation for Medical Education and Research, journalists will receive a behind-the-scenes, in-depth look at what’s new and what’s next in several medical specialties. Topics will include aging, cancer, brain injuries and diseases, transplant medicine, vaccines and developing technologies such as regenerative medicine, telemedicine and simulation-based medical training. The program will include hands-on activities. In addition to group sessions, journalists can personalize part of the program.
Members of the medical community are concerned with how they can make facts ‘attractive’ again and how trust in scientific information can be rebuilt, moving society towards a “post-trust” era. The Vaccine Communication symposia presented at the 2018 Society for Risk Analysis (SRA) Annual Meeting, co-organized by the Vienna Vaccine Safety Initiative, will explore concrete ways to improve vaccination policy moving forward in this “post-truth” era.
Borrowing methods from another field, researchers can now study the ever changing nature if Influenza A.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right